Herz Daniel, Merguerian Paul, McQuiston Leslie
Department of Urology, Nationwide Children's Hospital, Columbus, OH, USA; Division of Pediatric Urology, Children's Hospital at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Department of Urology, Seattle Children's Hospital, OA.9.220 - Urology, Seattle, WA 98105, USA; Division of Pediatric Urology, Children's Hospital at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
J Pediatr Urol. 2014 Aug;10(4):650-4. doi: 10.1016/j.jpurol.2014.06.009. Epub 2014 Jul 22.
The efficacy and utility of continuous antibiotic prophylaxis (CAP) in children with congenital antenatal hydronephrosis (ANH) is uncertain. The literature has both supportive and contradictory evidence. The growing trend not to place children with ANH on CAP has created varied clinical practice based on anecdotal individual case characteristics. Our goal was to compare individual infant characteristics between those children who were maintained on CAP to those that were not to try to determine predisposing risk factors to febrile.
All electronic medical records (EMRs) of children referred to our institution for congenital ANH over a period from 2001 to 2011 were examined. We excluded those referred for urinary tract infection (UTI) who had a history of congenital ANH. We also excluded those with incomplete records, or follow-up less than 2 years. Children were divided into two groups: those maintained on CAP (YCAP) and those not maintained on CAP (NCAP). Our primary endpoint was febrile UTI. Follow-up was at least 24 months. Demographic, perinatal and postnatal clinical data were recorded. Statistical analysis was performed using STATA Version 11.1.
Of the 405 children fitting inclusion criteria, 278 (68.6%) children were maintained on CAP and 127 (31.4%) were not on CAP. The incidence of prematurity, oligohydramnios, perinatal respiratory complications, use of perinatal antibiotics, circumcision status, renal anomalies, associated medical diagnoses, and low birth weight did not differ between the two groups. Overall the incidence of febrile UTI during the follow-up period was 22.2%. The incidence of febrile UTI between the YCAP and NCAP groups was significant (YCAP = 7.9% and NCAP 18.7%, p = 0.021). Multivariate logistic regression using CAP as the dichotomous dependent variable revealed that ureteral dilation, high-grade vesicoureteral reflux (VUR), and ureterovesical junction (UVJ) obstruction were independent risk factors for febrile UTI. More specifically, children with ureteral dilation >11 mm NOT maintained on CAP had a 5.54 (OR = 5.54; CI = 3.15-7.42, p = 0.001) fold increased risk of febrile UTI compared to those maintained on CAP.
The presence of ureteral dilation, high grade VUR, and UVJ obstruction were independent risk factors for development of UTI in children with congenital ANH. Therefore CAP may have a significant role in reducing the risk of febrile UTI in children with ANH with those identifiable risk factors, but otherwise seems unnecessary.
先天性产前肾积水(ANH)患儿持续抗生素预防(CAP)的疗效和实用性尚不确定。文献中有支持和矛盾的证据。越来越多不将ANH患儿进行CAP的趋势,导致基于个别病例特征的临床实践各不相同。我们的目标是比较接受CAP治疗的儿童与未接受CAP治疗的儿童的个体特征,以确定发热的易感风险因素。
检查了2001年至2011年期间转诊至我院的先天性ANH患儿的所有电子病历(EMR)。我们排除了有先天性ANH病史且因尿路感染(UTI)转诊的患儿。我们还排除了记录不完整或随访时间少于2年的患儿。患儿分为两组:接受CAP治疗的患儿(YCAP)和未接受CAP治疗的患儿(NCAP)。我们的主要终点是发热性UTI。随访时间至少为24个月。记录人口统计学、围产期和产后临床数据。使用STATA 11.1版进行统计分析。
在符合纳入标准的405名患儿中,278名(68.6%)患儿接受CAP治疗,127名(31.4%)未接受CAP治疗。两组患儿的早产、羊水过少、围产期呼吸并发症、围产期抗生素使用、包皮环切状态、肾脏异常、相关医学诊断和低出生体重的发生率无差异。总体而言,随访期间发热性UTI的发生率为22.2%。YCAP组和NCAP组发热性UTI的发生率有显著差异(YCAP = 7.9%,NCAP = 18.7%,p = 0.021)。以CAP为二分因变量的多因素逻辑回归显示,输尿管扩张、高级别膀胱输尿管反流(VUR)和输尿管膀胱连接部(UVJ)梗阻是发热性UTI的独立危险因素。更具体地说,输尿管扩张>11 mm且未接受CAP治疗的患儿发生发热性UTI的风险是接受CAP治疗患儿的5.54倍(OR = 5.54;CI = 3.15 - 7.42,p = 0.001)。
输尿管扩张、高级别VUR和UVJ梗阻是先天性ANH患儿发生UTI的独立危险因素。因此,对于有这些可识别风险因素的ANH患儿,CAP可能在降低发热性UTI风险方面发挥重要作用,但在其他情况下似乎没有必要。